BioCryst Pharmaceuticals, Inc., a leading biotech firm, revealed that Ireland’s Health Services Executive (HSE) has endorsed Orladeyo (berotralstat) for the regular prevention of repeated hereditary angioedema (HAE) attacks in suitable patients aged 12 and above. This endorsement enables Irish HAE patients to avail themselves of the pioneering oral, daily treatment aimed at minimizing HAE recurrences.
“The favorable decision by the HSE expands access to modern preventive measures, offering healthcare providers enhanced prescribing options and potentially providing HAE patients in Ireland an improved quality of life,” expressed Charlie Gayer, the chief commercial officer at BioCryst.
The HSE’s conclusion in Ireland follows the European Commission’s approval of Orladeyo in April 2021. Presently, Orladeyo is approved in 44 countries worldwide.
Orladeyo (berotralstat) is the groundbreaking oral solution specifically engineered to ward off hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 years and older. A single daily capsule acts as a deterrent against HAE attacks by reducing plasma kallikrein activity.
Orladeyo (berotralstat) acts as a plasma kallikrein inhibitor and is designated for the prevention of hereditary angioedema (HAE) attacks among individuals aged 12 years and beyond.
BioCryst Pharmaceuticals stands out as a global biotech entity passionately dedicated to enhancing the lives of those affected by hereditary angioedema and other uncommon disorders.